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Introduction: A system for monitoring the use of aphaeresis in the treatment of ulcer-
ative colitis (UC), named system for monitoring aphaeresis in ulcerative colitis (SiMAC),
was designed in 2006 in the Basque Country. In the present study, the opinion of the
clinicians who participated in SiMAC was evaluated, in order to identify the barriers and
gather suggestions that could improve implementation of this kind of system. Methods:
A mixed questionnaire was designed, in order to gather clinicians’ assessments of the
SiMAC monitoring system. Results:The response rate was 73.9% (17/23).The data from
40.96% (159/388) of patients with UC treated with aphaeresis was recorded. The main
reasons for not including the data from all treated patients were a lack of required data
or not meeting the study inclusion criteria. Positive aspects of the SiMAC were identiﬁed,
as the simplicity of data collection and its systematic, multi-center approach.The negative
aspects mentioned were the use of a local computer application and the lack of time for
health professionals to enter data. Discussion: The use of monitoring systems helps to
formalize the introduction of technologies of little-known effectiveness; involve clinicians
and medical societies in coming to agreement and obtaining information about the safety,
effectiveness or efﬁciency of new technologies; and provide relevant information to health-
care administrations for making decisions about the introduction of new technologies into
healthcare practice. In order for a monitoring system to work, the process must be straight-
forward. A minimum set of key variables that are easy to collect must be selected, and
an effort made to involve a range of stakeholders, especially institutions and scientiﬁc
societies, to support the work group.
Keywords: monitoring systems, product surveillance, post-marketing, technology assessment, biomedical, diffu-
sion of innovation, coverage with evidence, managed entry agreements
INTRODUCTION
Healthtechnologyassessment(HTA)isdesignedtoprovideinfor-
mation, based on scientiﬁc knowledge and a real-life context, to
inform decision-making at various levels in the health system.
However, when making decisions about the introduction of new
technologies, there may be doubts due to a lack of information
about effectiveness or because, when using the technology under
normal conditions, problems, or side effects arise that were not
predicted in the preliminary studies (Varela Lema et al., 2007).
In the case of medical devices, the CE mark guarantees that
the product meets the requirements of the European Directives
designed to ensure their safety and performance. However,the CE
markdoesnotguaranteetheclinicaleffectivenessorcosteffective-
nessoftheseproducts.Forthisreason,variousinitiativeshavebeen
implemented in the past decade with the aim of observing when
and how technology is used in real conditions,or in order to carry
out studies in which the safety and effectiveness of the technol-
ogy is assessed within a speciﬁc population or scenario (Frønsdal
etal.,2010).InSpain,aprocedurecalled“Coverageunderreview,”
has been designed for assessing technologies with high potential
for producing substantial improvements in health or in quality
of life, but for which there is not sufﬁcient information to make
pronouncements about their safety, effectiveness, and efﬁciency.
This procedure is used before the technologies can be funded in
general terms by the public health system.
In the Basque Country and Galicia, speciﬁc regulations deter-
mine that, depending on the available scientiﬁc evidence, some
new technologies may be considered as subject to special limi-
tations and controls or to special monitoring. This means that,
followingauthorizationforuse,theyremainsubjecttothespeciﬁc
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indication,implementation,andassessmentcriteriaestablishedby
the relevant bodies.
Underthislaw,theBasqueOfﬁceforHealthTechnologyAssess-
ment (Osteba) produced an assessment report on the use of
aphaeresis systems in treating inﬂammatory bowel disease (IBD;
Gutiérrez-IbarluzeaandArcelay,2004),technologythathasborne
the CE mark since 19991. This report suggested that the tech-
nology be monitored for treating ulcerative colitis (UC), given
the lack of scientiﬁc evidence found about its effectiveness and
the short monitoring periods previously implemented, which are
inappropriate for detecting safety problems in the medium- to
long-term. A research project was consequently designed, using
a computer application known as the system for monitoring
aphaeresisinulcerativecolitis(SiMAC,abbreviatedfromtheSpan-
ish; Ibargoyen-Roteta et al., 2006). This project was based on
the prior related recommendations of the Spanish Work Group
on Crohn’s Disease and Ulcerative Colitis (GETECCU); Cabriada
et al.,2006).
1http://www.adacolumn.com/
Twenty-three hospitals from all over Spain participated in this
project and data were collected from 195 patients with UC treated
with this type of system.
Because this was the ﬁrst system designed to monitor the use
of a new technology,the present work aims to reﬂect the opinions
of the clinicians who participated in data collection via SiMAC,
with the aim of identifying the difﬁculties that were encountered
and gathering suggestions about aspects that could improve the
implementation and participation of clinicians in data collection
of other monitoring systems.
MATERIALS AND METHODS
STUDY POPULATION
Clinicians responsible for collecting data from the 23 hospitals
participating in SiMAC.
STRUCTURE OF THE QUESTIONNAIRE
A mixed questionnaire was designed, with two sections
(see Figure 1). The ﬁrst section, labeled “Data of interest,” con-
tained questions related to the hospital, the situation in terms of
FIGURE1|S y s t e mf o rmonitoring aphaeresis in ulcerative colitis assessment questionnaire.The outcomes of the questionnaire had not been validated.
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IBD and UC, and the use of aphaeresis systems in each of the
hospitals.
The second part of the questionnaire was designed in order to
evaluate the SiMAC by the participating clinicians. This section
dealt with topics such as the suitability of the variables deﬁned for
treatmentmonitoring,themostappreciatedaspectsof thesystem,
the difﬁculties encountered,and the measures that could improve
participation of health professionals in this type of monitoring
system.
STUDY DESIGN
Transversal,descriptive study,carried out at the end of the SiMAC
data collection by sending an assessment questionnaire via email
totherepresentativehealthpractitionerateachhospital.Theemail
was used because of difﬁculties to contact health professionals by
telephone. The questionnaire was ﬁrst sent on 15.12.2009. Two
weeks later, a reminder was sent to those hospitals that had not
answered.A certiﬁcate accrediting participation in the assessment
study was sent to all practitioners who had responded to the
questionnaire.
RESULTS ANALYSIS
The numerical data related to the hospital and the number of
registered patients with IBD and UC, as well as the number of
patients treated with aphaeresis, have been summarized in the
formof absoluteandrelativefrequencies.Theanswerstotheopen
questions have been described in the text.
RESULTS
PARTICIPATION IN THE STUDY
The response rate to the questionnaire was 73.9% (17/23).
Figure 2 shows the location of the hospitals that partici-
pated in the SiMAC, with those that responded to the assessment
questionnaire shown in black.
DATA OF INTEREST ABOUT PARTICIPATING HOSPITALS
Thesearetertiaryhospitals,forwhichthepopulationcoverage,the
number of registered patients with IBD and speciﬁcally, with UC,
are presented in Table 1.
Table 2 shows the year in which aphaeresis treatment was ﬁrst
usedineachhospital,thenumberof patientswithtreatedIBDand
UC and the number of treated UC patients included in SiMAC.
It can be observed that there are six hospitals that began using
aphaeresis systems before 2004.
SiMAC ASSESSMENT BY CLINICIANS
Table 2 reveals that 8 of the 17 hospitals included less than 50%
of the UC patients that they had treated with aphaeresis. When
asked why they had not included all the patients in SiMAC,of the
14 centers that answered this question,eight blamed a lack of data
about these patients; three explained that they were patients with
Crohn’s disease or indeterminate colitis; another four indicated
that it was due to the inclusion criteria not being met (funda-
mentally, because no endoscopy had been performed, which was
necessary for calculating the level of UC activity within the stated
time periods); and one cited a work overload and not knowing
how to involve the other department which was responsible for
the treatment,in the data collection.
FIGURE 2 | Distribution of participating hospitals according to whether
or not they responded to the questionnaire.
Sixcliniciansansweredthequestionabouttheexistenceof spe-
ciﬁcindicationsfortheuseof aphaeresis,witheachcitingdifferent
indications: steroid-dependent or -resistant IBD; UC in general;
steroid-dependent UC following the failure of immunosuppres-
siveagents;steroid-dependentorresistantUC;asatreatmentprior
to surgery; or in mild to moderate and steroid-dependent UC.
Only two participants considered that the variables that had
been deﬁned for treatment monitoring were not the right ones.
One justiﬁed this by saying that there are too many and that some
do not provide information that is of interest to the study, which
hinders data collection.
Of the 15 participants who considered the deﬁned variables
to have been well-chosen, three suggested making some changes
related to deﬁning collection times, with a clearer deﬁnition of
the possible indications of aphaeresis and the use of an activ-
ity index that does not require endoscopy. With regard to those
aspects of the SiMAC that received the best feedback, ﬁve partici-
pantsappreciatedthedesignof asystematiccollectionmethodfor
patient treatment, monitoring, and control; three referred to the
simplicity of data collection and use of the computer application;
four highlighted the multi-center nature of the study; and ﬁnally,
two participants referred to the persistence of the sponsor group
and the ease of communication with the same.
The difﬁculties encountered by participants were the follow-
ing: seven had some kind of problem installing the application or
withdata-sending;threestatedthattheydidnothavetimetoenter
the data; another three participants pointed to their lack of infor-
mation about patients for whom the data was collected before the
startof theproject;twoindicatedthattheyhadtoomanyvariables
to collect; and one claimed to have had sparse information about
the results of their patients in the medium- and long-term.
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Table 1 | Characteristics of the hospitals that responded to the questionnaire.
Population covered Patients with IBD Patients with UC Percentage of IBD patients with UC
Hospital 1 300,000 750 375 50
Hospital 2 700,000 1000 500 50
Hospital 3 300,000 700 300 42.86
Hospital 4 500,000 368 190 51.63
Hospital 5 250,000 800 350 43.75
Hospital 6 500,000 – – –
Hospital 7 450,000 986 450 45.64
Hospital 8 350,000 800 450 56.25
Hospital 9 400,000 1525 741 48.59
Hospital 10 250,000 700 320 45.71
Hospital 11 210,000 550 350 63.64
Hospital 12 215,000 750 319 42.53
Hospital 13 – 15 13 86.67
Hospital 14 600,000 300 200 66.67
Hospital 15 300,010 348 156 44.83
Hospital 16 250,000 500 250 50
Hospital 17 800,000 700 – –
Table 2 | Aphaeresis in the participating hospitals that responded to the questionnaire.
Hospital Aphaeresis
start year
IBD patients
with aphaeresis
UC patients
with aphaeresis
UC patients with
aphaeresis in SiMAC
Percentage UC patients
with aphaeresis in SiMAC
Hospital 1 2004 27 24 22 91.67
Hospital 2 2006 20 15 11 73.33
Hospital 3 2003 45 40 3 7 .5
Hospital 4 2005 19 19 11 57 .89
Hospital 5 2003 16 13 7 53.85
Hospital 6 2004 50 45 8 17 .78
Hospital 7 2006 10 8 3 37 .5
Hospital 8 2005 14 13 4 30.77
Hospital 9 2003 27 20 2 10
Hospital 10 2004 12 8 8 100
Hospital 11 2003 20 17 8 47 .06
Hospital 12 2007 9 9 6 66.67
Hospital 13 2007 3 3 3 100
Hospital 14 2002 80 60 10 16.67
Hospital 15 2002 35 25 20 80
Hospital 16 2004 40 36 32 88.89
Hospital 17 2006 33 33 1 3.03
Total 460 388 159 40.98
Incentivesormeasurespointedouttoimproveparticipationin
a monitoring system were the following: provide a data manager
or person to collect the required data (four participants); have a
permanent database to facilitate publications (three participants);
facilitatetheinclusionof morepatientsinthedatabase(threepar-
ticipants); prioritize one or more meetings between researchers
and participants (three participants); reduce the work load of
healthcare professionals (one participant); ﬁnancial and curric-
ular incentives (one participant); and the creation of an online
(rather than local) database for data entry (one participant).
Of the 14 participants who answered the question on the par-
ticipation of industry, one believed that industry players should
not participate or, if they did, should do as little as possible; ﬁve
participants considered that they could provide the material (the
aphaeresis columns, in this case) or ﬁnance treatment in centers
that are without coverage; four suggested that they could pro-
vide data managers;another participant suggested that they could
take charge of maintaining the project database and webpage;and
another that they could send reminders to participants to col-
lect the pending data. One participant pointed out that the legal
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framework would pose barriers to industry players providing this
type of help.
With regard to how to improve data collection for tech-
nology monitoring, six participants suggested that an online
database could be designed, easier to use and with less vari-
ables; three proposed that the care load of the healthcare
professional could be reduced or that the research could be
included as part of their professional responsibilities; one
indicated that having an electronic patient record that already
includes these data would facilitate data collection; another that
it would be improved by creating databases into which all
treated patients could be entered (and not only some cases);
and ﬁnally, one considered that the process would improve
if it was done prospectively, using a data collection program
with an easier interface. All these results are presented in
Table 3.
Table 3 | System for monitoring aphaeresis in ulcerative colitis assessment by clinicians.
Questions n
Which are the reasons for not including all treated patients? (n=14)
Lack of data about those patients 8
Crohn’s disease or Indeterminate colitis 3
Not meeting inclusion criteria 4
Work overload and not knowing how to involve the other department which was responsible for the treatment, in the data collection 1
Deﬁned monitoring variables are the correct ones? (n=17)
Yes/No 15/2
Would you modify any of them? (n=17)Yes/No 4/13
What aspects did you like about SiMAC (n=16)
Systematic collection method for patient treatment, monitoring and control 5
Simplicity of data collection and the use of computer application 3
Multi-center nature of the study 4
Persistence of the sponsor group and the ease of communication with the same 2
They liked the system 2
Which difﬁculties encountered when participating in this project? (n=17)
Problems installing the application or with data-sending 7
No time to enter data 3
Lack of information about patients for whom data was collected before the start of the project 3
Too many variables to collect 2
Sparse information about patient results in the medium-and long-term 1
None 1
Which kind of incentives or measures would improve participation of health professionals in data collection? (n=13)
Provide a data manager or person to collect the required data 4
Permanent database to facilitate publications 3
Facilitate the inclusion of more patients in the database 3
Prioritize one or more meetings between researchers and participants 3
Reduce the workload of health care professionals 1
Financial and curricular incentives 1
Creation of an online (rather than local) database for data entry 1
Its sufﬁciently incentivized 1
In which way could industry participate in such a system? (n=14)
Industry players should not participate, or if they did, should do as little as possible 1
They could provide the material (the aphaeresis columns, in this case) or ﬁnance treatment in centers that have no coverage 5
Provide data managers 4
Take charge of maintaining project database and webpage 1
Send reminders to participants to collect the pending data 1
There are legal framework that pose barriers to industry players providing this type of help 1
Industry is necessary to carry out these type of projects 1
How do you think we could improve data collection in a technology monitoring system? (n=13)
Designing an online database 6
Reducing the care load of health professionals or including research as part of their professional responsibilities 3
Having an electronic patient record that already includes these data 1
Creating databases into which all treated patients could be entered 1
Improving the process if done prospectively, using a data collection program with an easier interface 1
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DISCUSSION
Some options for obtaining the necessary information for mon-
itoring health technology include the use of administrative data-
bases, surveillance activities, or databases obtained from more
speciﬁc activities, such as records of particular technologies or
diseases(Frønsdaletal.,2010).Inthepresentcase,inordertomon-
itor the effectiveness and safety of aphaeresis systems in treating
UC, the patients treated with these systems were speciﬁcally reg-
istered. An installable application was designed for this purpose,
with variables deﬁned in advance by a group of IBD experts from
the GETECCU group (Ibargoyen-Roteta et al., 2006). The reason
for developing an installable application was to provide every par-
ticipating center with the option of maintaining and exploiting
their own local database. It was considered that this might be an
incentive for increasing the level of participation in the SiMAC.
However,oncetheevaluationstudyhadbeencompleted,itbecame
clear that participants had had some problems, speciﬁcally with
installingtheapplicationandsendingdatatothecentraldatabase.
This is a very important point, as it may have inﬂuenced the data
collectionandtheeaseof thewholeprocess.Infact,asindicatedby
some participants, the use of an online application, as well as the
existenceof theelectronicpatientrecord(VarelaLemaetal.,2007)
are options that could have simpliﬁed data collection. The ease of
data collection has a major impact on whether or not participants
meetthedeadlineforinclusionof datafromanystudyof thistype
(Ministerio de Sanidad y Consumo, 2007).
Even though initially SiMAC was designed for collecting data
in a prospective manner, it was decided that the inclusion of data
from those patients who had started aphaeresis treatment before
the start of the study should be allowed,since many hospitals had
already started to use these systems prior to 2004.
Whenworkingwithtechnologiesusedinpathologiesorcondi-
tions with low incidence, or with applications in a small number
of patients, national and international collaborations could facil-
itate the data collection process. In the present case, an attempt
was made to involve the greatest possible number of Spanish hos-
pitals in order to collect data from the greatest possible number of
patients, and thus build a sufﬁciently large sample as to be able to
draw conclusions that are relevant to clinical practice.
This type of collaboration facilitates mechanisms for sharing
protocols,andevendataonresultsfromindividualpatients,which
makes it possible to draw more reliable conclusions within the
shortest possible time. In this respect, it is worth mentioning the
effort carried out at European level by the EUnetHTA network in
order to describe the situation in Europe in this area, and search
for parameters for standardizing the design and operation of a
monitoring system2.
With regard to the low percentages of UC patients treated with
aphaeresis systems that were included by some centers, clinicians
state that this was mainly due to the impossibility of ﬁlling in the
data for some of the variables required in SiMAC. According to
opinions presented in other studies,focusing the monitoring on a
2http://www.eunethta.net/en/Public/Work_Packages/EUnetHTA-Project-2006-
08/WP7/
minimumsetof keydataisessentialinordertobeabletomeetthe
proposed target (Frønsdal et al., 2010). In fact, the clinicians who
participated in SiMAC proposed reducing the number of vari-
ables to be collected for each patient,and replacing the index used
for measuring UC activity with another that would not require
endoscopy.
Another of the issues ﬂagged by participants as a factor hinder-
ing data collection is their lack of time for dedicating themselves
to this type of task. Reducing the care load for professionals par-
ticipating in this type of initiatives, or including the research as
an activity that is part of standard hospital tasks, are some of the
suggestions made to remedy this. In this regard,the potential role
of the electronic patient record should not be overlooked. This
is starting to be used, and should be sufﬁciently ﬂexible so as to
be able to include the data necessary for monitoring studies, and
from which it should be easy to extract data for analysis, without
overloading medical practitioners even more. Study participants
alsosuggestedcontractingdatamanagersasanotherpossiblesolu-
tion, although this would pose a funding problem for healthcare
organizations, since the funds dedicated to these ends are limited
(Frønsdal et al.,2010).
The funding obtained for carrying out the present work was
restricted, since the design and setting up of the SiMAC mon-
itoring system was funded through the Spanish national health
system’s Quality Plan 2006, but not the monitoring of the data
collection by the hospitals participating in the study. The project
wasabletobecompletedthankstotheinvolvementof GETECCU,
which enabled closer contact with clinicians, provided informa-
tion about the project in its annual meeting and promoted data
collection. Increased funding would have made it possible to hold
regular meetings between the principal researchers and the par-
ticipating professionals, which the latter raised as an aspect that
could improve the functioning of this type of monitoring system.
Industry players also participated in completing the study to
a certain extent, by personally reminding the participants, during
their visits, to complete the monitoring of the patients that they
had included in the records. As a possible solution to the fund-
ingproblems,theEuropeanCommissionsignaledthattechnology
monitoring could be funded by the industry in general (Euro-
pean Commission,2004,2009),despite the fact that it has already
invested large amounts of money in the process of technology
acceptance by the competent authorities and in safety monitoring
systems. In the present case,only one participant held the opinion
thatindustryshouldnotparticipate,orthatitshoulddosoaslittle
aspossible.However,mostparticipantsoffereddifferingvisionsof
how industry could participate, such as facilitating the contract-
ing of data managers or funding the columns or the treatment.
Whatever the case, it would be fundamental to recognize whether
industry participation inﬂuenced data collection in any way, dis-
closing the existence or absence of conﬂicts of interest. There are
currently a variety of initiatives for bridging the “know-do” gap
andforimplementinghealthtechnologiesinwhichagreementsare
reached between service providers and technology producers. In
thisvein,NICE(theUK’sNationalInstituteforhealthandClinical
Excellence) has proposed mechanisms for improving access to
new treatments (Raftery, 2001); and joint risk agreements with
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industry have now been developed in order for health technolo-
gies to be introduced in a prudent manner, while simultaneously
reducing timescales (Hutton et al., 2007; Klemp et al., 2011; US
Department of Health and Human Services, 2011).
CONCLUSION
Finally, while keeping in mind the small sample size (despite
having included the opinions of almost 74% of the healthcare
professionals), we can conclude that the use of monitoring sys-
tems can help us to: (a) create protocols for the introduction of
technologies of little-known effectiveness, so that it is better con-
trolled and has a better guarantee in terms of patient beneﬁts; (b)
involve clinicians and medical societies in agreements about and
obtainment of information on new technologies; (c) obtain cor-
roborated, objective information about the safety, effectiveness,
andefﬁciencyof newtechnologies;and(d)providerelevantinfor-
mation to the health administrations for making decisions about
the introduction of new technologies into medical practice.
However, in order for a monitoring system to work, the fol-
lowing points need to be taken into account: (a) the necessity of
facilitating the process; (b) the selection of a minimum set of rel-
evant variables that are easy to collect [methods for identifying
outcomes of interest could be used, such as the one developed by
GRADE (Ibargoyen-Roteta et al.,2010)]; and (c) that the involve-
ment in these systems of different stakeholders is fundamental,
particularly institutions (recognition of healthcare professionals’
work and the necessity of funding the procedure) and scientiﬁc
societies (support for the work group),an example of which is the
role played by GETECCU in this project.
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